Find Funding Opportunities

The purpose of this funding opportunity announcement (FOA) is to invite applications to continue support of a national program of mentored research career development for junior neurosurgeon faculty at institutions nationwide that support neurosurgical research. The goal of the program is to expand the cadre of neurosurgeon investigators trained to conduct research into neurological disorders, making use of their neurosurgical training.

This notice informs applicants of a change to the Key Dates for PA-18-705 "SBIR Technology Transfer (R43/R44 Clinical Trial Not Allowed)". This Funding Opportunity Announcement (FOA) has been extended by one additional council round to expire on September 6, 2021. Due to the extension, the following date has been added: New, Renewal, Resubmission, and Revision Application Due Date: September 5, 2021. The following section of PA-18-705 "SBIR Technology Transfer (R43/R44 Clinical Trial Not Allowed)" has been modified, as indicated below.

This notice informs applicants of a change to the Key Dates for PAR-21-059 "Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)". Due to an error with the open date of this Funding Opportunity Announcement (FOA), the first receipt date for this FOA has been moved back to March 15, 2021.

The NIH Blueprint for Neuroscience Research is a collaborative framework through which 14 NIH Institutes, Centers and Offices jointly support neuroscience-related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders (for further information, see http://neuroscienceblueprint.nih.gov/). To facilitate biotherapeutic discovery and development by the neuroscience community, the NIH Blueprint for Neuroscience Research has established the Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics), a collection of contract service providers and consultants with extensive industry experience in the areas of pharmacokinetics, toxicology, manufacturing, and Phase I clinical safety testing. A planned Funding Opportunity Announcement (FOA) will solicit applications from investigators seeking funding through a UG3/UH3 phased cooperative agreement mechanism to help advance their biologic drug discovery and development projects into the clinic. This FOA will support preclinical discovery and development of potential therapeutic biologics and biotechnology products including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program. To be eligible for the BPN-Biologics program, an applicant must have identified one or more lead biologic agent(s) with e

The NIH Blueprint for Neuroscience Research announces its intention to publish a Funding Opportunity Announcement (FOA) for investigators seeking support from the Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics). Applicants will be encouraged to utilize a customized set of contract resources and consultants from the BPN-Biologics Network to help advance their neuroscience-focused biotherapeutic discovery and development projects into the clinic. This Notice is provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Details of the planned FOA are provided below. The FOA is expected to be published in the spring of 2021 with an expected application due date in the summer of 2021.

The NIH Countermeasures Against Chemical Threats (CounterACT) program intends to publish a Funding Opportunity Announcement (FOA) to solicit applications to recruit Early Stage Investigators (ESI) to pursue exploratory/developmental, applied, proof of concept, or high risk-high impact research to discover safe and effective therapeutics to mitigate toxicities resulting from exposures to highly toxic chemicals.

This initiative will support (1) observational research to understand the role of structural racism and discrimination (SRD) in causing and sustaining health disparities, and (2) intervention research that addresses SRD in order to improve minority health or reduce health disparities.

The purpose of this Notice is to inform potential applicants that the Helping End Addiction Long-term (HEAL) Initiative and National Institute of Neurological Disorders and Stroke (NINDS), intends to publish a funding opportunity announcement RFA-21-15 as well as to announce a pre-application webinar on Thursday, March 11, 2021 from 3:00-4:00 pm EDT (12:00 -1:00pm PDT). This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in March 2021 with an expected application due date in April 2021. This FOA will utilize the U19 Research Program Cooperative Agreements activity code. Details of the planned FOA and pre-application webinar are provided below.

The purpose of this Notice is to inform potential applicants that the Helping End Addiction Long-term (HEAL) Initiative and National Institute of Neurological Disorders and Stroke (NINDS), intends to publish a funding opportunity announcement RFA-21-16 as well as to announce a pre-application webinar on March 11, 2020 from 3:00-4:00 pm ET (12:00 -1:00pm PDT). This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in March 2021 with an expected application due date in April 2021. This FOA will utilize the R34 Planning Cooperative Agreement activity code. Details of the planned FOA and pre-application webinar are provided below.

The purpose of this Notice is to announce the intention to issue an FOA to solicit new and renewal applications for autism centers of excellence (ACE) R01 Networks. A companion FOA will solicit applications for ACE Centers supported by the P50 activity code (see NOT-HD-21-007). An individual may serve as the Principal Investigator for an ACE Center or Network on only one application.